UPDATE – Nutriband Signs Associate Partnership with Charlotte FC
Nutriband Inc. (NASDAQ:NTRB) has announced signing an Associate Partnership agreement with Charlotte FC. The partnership aims to increase visibility for Nutriband's products, particularly AI Tape, which is manufactured at their Pocono Pharmaceutical facility in North Carolina.
The company plans to leverage this partnership to promote their AVERSA platform technology, which they position as potentially becoming the world's first abuse deterrent patch platform for chronic pain management.
Nutriband Inc. (NASDAQ:NTRB) ha annunciato di aver firmato un accordo di partnership associativa con Charlotte FC. L'obiettivo della partnership è aumentare la visibilità dei prodotti di Nutriband, in particolare AI Tape, che è prodotto presso il loro stabilimento farmaceutico di Pocono nella Carolina del Nord.
L'azienda prevede di sfruttare questa partnership per promuovere la loro tecnologia della piattaforma AVERSA, che si propone di diventare potenzialmente la prima piattaforma di cerotti deterrenti per abusi al mondo per la gestione del dolore cronico.
Nutriband Inc. (NASDAQ:NTRB) ha anunciado la firma de un acuerdo de asociación con Charlotte FC. La asociación tiene como objetivo aumentar la visibilidad de los productos de Nutriband, en particular AI Tape, que se fabrica en su instalación farmacéutica de Pocono en Carolina del Norte.
La empresa planea aprovechar esta asociación para promover su tecnología de plataforma AVERSA, que posicionan como potencialmente la primera plataforma de parches disuasorios de abuso en el mundo para el manejo del dolor crónico.
Nutriband Inc. (NASDAQ:NTRB)가 Charlotte FC와 협회 파트너십 계약을 체결했다고 발표했습니다. 이 파트너십의 목표는 Nutriband의 제품, 특히 노스캐롤라이나의 Pocono 제약 시설에서 제조되는 AI Tape의 가시성을 높이는 것입니다.
회사는 이 파트너십을 활용하여 만성 통증 관리에 대한 세계 최초의 남용 방지 패치 플랫폼이 될 가능성이 있는 AVERSA 플랫폼 기술을 홍보할 계획입니다.
Nutriband Inc. (NASDAQ:NTRB) a annoncé la signature d'un accord de partenariat associatif avec Charlotte FC. L'objectif de ce partenariat est d'accroître la visibilité des produits de Nutriband, notamment AI Tape, qui est fabriqué dans leur installation pharmaceutique de Pocono en Caroline du Nord.
L'entreprise prévoit d'exploiter ce partenariat pour promouvoir sa technologie de plateforme AVERSA, qu'elle positionne comme étant potentiellement la première plateforme de patchs dissuasifs contre les abus au monde pour la gestion de la douleur chronique.
Nutriband Inc. (NASDAQ:NTRB) hat die Unterzeichnung eines Partnerschaftsvertrags mit Charlotte FC bekannt gegeben. Ziel der Partnerschaft ist es, die Sichtbarkeit der Produkte von Nutriband zu erhöhen, insbesondere AI Tape, das in ihrer pharmazeutischen Einrichtung in Pocono, North Carolina, hergestellt wird.
Das Unternehmen plant, diese Partnerschaft zu nutzen, um ihre Plattformtechnologie AVERSA zu fördern, die sie als potenziell erste missbrauchsverhindernde Patch-Plattform für das Management von chronischen Schmerzen positionieren.
- Local manufacturing presence in Charlotte region through Pocono subsidiary
- Marketing partnership with Charlotte FC to increase brand visibility
- None.
ORLANDO, Fla., April 04, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (the “Company”)(NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced that it has signed an Associate Partnership agreement with Charlotte FC.
The Company intends to use the Associate partnership to build visibility for its brands such as AI Tape which is manufactured locally in the Charlotte area.
“We are very excited to partner with an organization such as Charlotte FC as an Associate Partner. Manufacturing many of our products locally in the Charlotte region through our Pocono subsidiary makes this relationship special.’’
AI Tape is manufactured in the USA at the Company's Pocono Pharmaceutical facility in North Carolina.
The Company also intends to use the relationship to promote its platform technology AVERSA and raise awareness for the technology which has the potential to be the World’s first and only abuse deterrent patch platform for managing chronic pain.
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2024 and Forms 10-Q, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
What is the purpose of Nutriband's (NTRB) partnership with Charlotte FC?
Where is Nutriband's (NTRB) AI Tape manufactured?
What is Nutriband's (NTRB) AVERSA technology?
What products will Nutriband (NTRB) promote through the Charlotte FC partnership?
